证券代码：002412 证券简称：汉森制药 湖南汉森制药股份有限公司 投资者关系活动记录表 编号：2015-002 | --- | --- | --- | |-----------------------------|------------------------------------------|----------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动类别 | □ 新闻发布会 □路演活动 □ 现场参观 □ 其他 | （请文字说明其他活动内容） | | 参与单位名称及 人员姓名 | 方正证券股份有限公司 | 吴斌 | | | | | | 时间 | 2015 年 5 月 19 | 日 | | 地点 | 公司一楼会议室 | | | 上市公司 接待人员姓名 | 刘正清、杨丽霞、金刚、杨湘 | | | 投资者关系活动 主要内容介绍 | 二、参观厂区及募投项目生产线 | 一、公司经营情况交流（后附纪要） | | 附件清单 | 无 | | 湖南汉森制药股份有限公司 调研会谈纪要 ...

证券代码：002412 证券简称：汉森制药 湖南汉森制药股份有限公司 投资者关系活动记录表 编号：2015-001 | --- | --- | --- | |-------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动类别 | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ 其他 | （请文字说明其他活动内容） | | | 大禹资产管理有限公司 ...

Group 1: Company Overview and Strategic Direction - The company is focusing on the cultivation of traditional Chinese medicinal materials, primarily Zhiqiao, to meet raw material demands and respond to government policies [4] - The company aims to establish "Xiang Jiuwai" as a leading brand in the market [4] - Future plans include collaborating with influential hospitals in surrounding cities for health check-ups and rehabilitation services [4] Group 2: Market Challenges and Sales Performance - The sales of Si Mo Tang have not met expectations due to several factors, including a challenging OTC environment, media events affecting consumer perception, and the suspension of basic medicine inclusion in various provinces [6] - In 2014, approximately 70% of Si Mo Tang's revenue came from OTC sales, which has been significantly impacted [6] - Sales in Hunan have remained flat this year, with some progress in market expansion in Xiangnan and Xiangxi regions [6] Group 3: Investment and Financial Planning - The company is gradually advancing its investment in the health industry, with a focus on feasibility studies for medical services [5] - The investment amount for new projects will be determined based on the company's capacity [5] - The company has previously published a feasibility study report on the cultivation of medicinal materials [5] Group 4: Acquisition and Market Positioning - The company continues to prioritize acquisitions as a key strategy, given the lengthy and costly process of developing new traditional Chinese medicines [8] - The integration of Yongzitang's sales has faced challenges, but improvements are being made as stakeholders understand the long-term benefits [7] - Yongzitang's sales were projected to reach 200 million, but this target was not met due to price adjustments and the overall OTC environment [7] Group 5: Regulatory and Compliance Issues - Yongzitang's products have been included in the medical insurance directory in thirteen provinces, with hopes for national coverage [8] - The company is actively working on pricing adjustments and tendering processes to align with market standards [8] - The future handling of the major shareholder's asset, Nanyue Pharmaceutical, remains uncertain as it is undergoing GMP certification [8]

证券代码：002412 证券简称：汉森制药 湖南汉森制药股份有限公司 投资者关系活动记录表 编号：2015-003 | --- | --- | --- | |--------------------|------------------------|----------------------------| | | √ | 特定对象调研 □分析师会议 | | | □ 媒体采访 □业绩说明会 | | | 投资者关系活动类别 | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ 其他 | （请文字说明其他活动内容） | | 参与单位名称及 | 广发资管 | 毛丁丁 | | 人员姓名 | 红塔红土 | 谭权胜 | | | | | | | 彤源投资 | 谷玺 | | | 海通资管 | 刘彬 | | | SMC 基金 | 王帅 | | | 国都证券 | 赵玥 | | | 中信产业基金 | 陈宇 | | | 坚木投资 | 刘晓霞、刘彬阳 | | | 国都资管 | 姚巍 | | | 中欧博瑞 | 汪洋、张宪强 | | | 泰康人寿 | 殷萌萌 | | | 中欧基金 | 龙宇飞 | 1 | --- ...

证券代码：002412 证券简称：汉森制药 湖南汉森制药股份有限公司 投资者关系活动记录表 编号：2016-001 | --- | --- | --- | |-------------------------|----------------------------|----------------------------| | | | | | | √ 特定对象调研 □分析师会议 | | | | □ 媒体采访 □业绩说明会 | | | 投资者关系活动类别 | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ 其他 | （请文字说明其他活动内容） | | | 西南证券 | 何治力 | | | 东兴证券 | 缪牧一 | | | | | | | 熵一资本 | 田开锐、匡野 | | 参与单位名称及 人员姓名 | 熵一贯喜 | 游军、张旭、徐亮 | | | 建鸿达投资 | 刘景、林清风 | | | 国信证券 | 张攻 | | 时间 | 2016 年 11 月 23 | 日 | | 地点 | 公司一楼会议室 | | | | | | | 上市公司 接待人员姓名 | 刘厚尧、杨湘 | | 1 | ...

证券代码：002412 证券简称：汉森制药 湖南汉森制药股份有限公司 投资者关系活动记录表 编号：2016-002 | --- | --- | --- | |--------------------|-----------------------------------|----------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动类别 | □ 新闻发布会 □路演活动 □ 现场参观 | | | | □ 其他 | （请文字说明其他活动内容） | | 参与单位名称及 | 吴学贵 | | | 人员姓名 | 周光华 | | | | 黄子生 | | | | 吴丁杰 | | | | 雷志鹏 | | | | 邓彬城 | | | | 张颖国 | | | | 李智雄 | | | | 黄国权 | | | | 陈少仲 | | | | 蔡丽 | | | | 梁亚玲 | | 1 | --- | --- | |-----------------------------|----------------------- ...

Financial Performance - The company's revenue for Q3 2022 was CNY 218,470,759.89, an increase of 0.76% year-on-year, while the revenue for the year-to-date period reached CNY 681,150,652.08, up 3.22% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2022 was CNY 51,192,368.36, representing a growth of 19.45% year-on-year, and the year-to-date net profit was CNY 130,074,008.87, an increase of 14.61%[4] - The basic earnings per share for Q3 2022 was CNY 0.1017, up 19.37% year-on-year, with diluted earnings per share also at CNY 0.1017[4] - Total operating revenue for the period reached ¥681,150,652.08, an increase of 3.7% compared to ¥659,918,134.34 in the previous period[22] - Net profit attributable to shareholders was ¥130,074,008.87, representing a 14.6% increase from ¥113,492,866.04 year-over-year[23] - Basic and diluted earnings per share increased to ¥0.2585 from ¥0.2255, reflecting a growth of 14.0%[24] Assets and Liabilities - Total assets at the end of Q3 2022 amounted to CNY 2,326,803,516.30, reflecting a growth of 10.21% compared to the end of the previous year[4] - The total assets of the company reached ¥2,326,803,516.30, an increase from ¥2,111,282,192.35 at the beginning of the year, reflecting a growth of 10.2%[20] - The company's accounts receivable rose to ¥244,069,859.79, compared to ¥207,401,998.50 at the start of the year, indicating an increase of 17.6%[20] - The total liabilities rose to ¥454,999,569.04, compared to ¥368,989,659.95 in the previous period, marking a 23.3% increase[23] - The total liabilities include accounts payable of ¥37,720,362.29, down from ¥51,440,181.32, indicating a decrease of 26.7%[20] Cash Flow - Cash flow from operating activities showed a net outflow of CNY 99,673,861.60 year-to-date, a significant decrease of 44.28% compared to the same period last year[4] - Cash flow from operating activities decreased to ¥715,181,968.17 from ¥779,328,523.24, a decline of 8.2%[25] - The net cash flow from operating activities for Q3 2022 was ¥99,673,861.60, a decrease of 44.3% compared to ¥178,868,988.40 in Q3 2021[26] - The total cash inflow from operating activities was ¥727,909,881.30, compared to ¥793,862,474.10 in the same quarter last year[26] - The total cash outflow from operating activities was ¥628,236,019.70, slightly higher than ¥614,993,485.70 in Q3 2021[26] Investments and Financing - The net cash flow from investing activities increased by 59.84% year-on-year, primarily due to an increase in cash received from purchasing bank wealth management and structured deposit products[11] - The net cash flow from financing activities increased by 432.43% year-on-year, mainly due to an increase in cash received from bank loans amounting to CNY 20,000,000[13] - Total cash inflow from investment activities was ¥105,725,650.98, significantly higher than ¥9,451,927.51 in the previous year[26] - The net cash flow from investment activities was -¥60,548,911.08, improving from -¥150,779,901.61 in Q3 2021[26] - Cash inflow from financing activities totaled ¥151,504,745.40, up from ¥130,153,195.20 in the same quarter last year[26] - The net cash flow from financing activities was ¥18,628,464.93, a turnaround from -¥5,603,689.48 in Q3 2021[26] Shareholder Information - The company’s total equity attributable to shareholders at the end of Q3 2022 was CNY 1,871,803,947.26, a growth of 7.43% compared to the end of the previous year[4] - The total equity attributable to shareholders increased to ¥1,871,803,947.26, up from ¥1,742,292,532.40, a growth of 7.4%[23] - The total number of common shareholders at the end of the reporting period is 33,824[15] - The largest shareholder, Hainan Hansen Holdings (Limited Partnership), holds 42.13% of the shares, totaling 212,006,189 shares[15] Other Income and Expenses - The company’s other income increased by 208.05% year-on-year, mainly due to a tax reward received from the local government amounting to CNY 2,844,100.00[9] - Research and development expenses for the period were ¥33,008,550.96, compared to ¥26,339,208.61 in the previous period, indicating a 25.4% increase[23] - Other comprehensive income after tax decreased to -¥1,912,591.42 from ¥7,803,735.27, reflecting a significant decline[24] - The total comprehensive income for the period was ¥128,161,417.45, compared to ¥121,296,601.31 in the previous period, an increase of 5.7%[24] Audit Information - The company did not undergo an audit for the Q3 report[28]

证券代码：002412 证券简称：汉森制药 公告编号：2022-026 湖南汉森制药股份有限公司 关于参加 2022 年湖南辖区上市公司投资者 网上集体接待日活动的公告 本公司及全体董事保证公告内容真实、准确和完整，不存在虚假记载、误 导性陈述或者重大遗漏。 为进一步加强与广大投资者的沟通交流，湖南汉森制药股份有限公司（以下 简称"公司"）将参加由中国证券监督管理委员会湖南证监局、湖南省上市公司 协会与深圳市全景网络有限公司联合举办的"湖南辖区上市公司投资者网上接待 日"活动，现将有关事项公告如下： 本次网上接待日活动将采取网络远程的方式举行，投资者可以登录"全景路 演"网站（http://rs.p5w.net），参与本次投资者网上接待日活动，活动时间为 2022 年 09 月 29 日（星期四）下午 15：30 至 17：00。 届时公司董事会秘书、证券事务代表将通过网络在线问答互动的形式，就投 资者关心的问题进行沟通与交流。 欢迎广大投资者积极参与。 | --- | --- | --- | |-------|-------|-------------------------------| | | | 湖南 ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥462,679,892.19, representing a 4.42% increase compared to ¥443,087,312.44 in the same period last year[17]. - The net profit attributable to shareholders was ¥78,881,640.51, an increase of 11.67% from ¥70,635,880.51 in the previous year[18]. - Basic earnings per share rose to ¥0.1568, reflecting an increase of 11.68% from ¥0.1404 in the previous year[18]. - The total profit for the same period was CNY 89.18 million, up 11.59% compared to the previous year[28]. - The company's total revenue for the first half of 2022 was CNY 462.68 million, representing a year-on-year increase of 4.42%[28]. - The company's total profit for the first half of 2022 was CNY 89,176,229.11, compared to CNY 79,911,966.72 in the same period of 2021, indicating a growth of around 11.6%[124]. - The company's total comprehensive income for the first half of 2022 was CNY 80,297,117.33, compared to CNY 69,801,420.66 in the same period of 2021, reflecting an increase of approximately 15%[125]. Cash Flow and Financial Position - The net cash flow from operating activities decreased by 52.68%, amounting to ¥54,750,153.07 compared to ¥115,705,962.98 in the same period last year[18]. - The net cash flow from operating activities decreased to ¥54,750,153.07 in the first half of 2022, down 52.7% from ¥115,705,962.98 in the same period of 2021[130]. - The net increase in cash and cash equivalents was CNY 25,966,831.51, a decline of 66.82% from CNY 78,270,772.81 in the previous year[32]. - The company's cash and cash equivalents increased to ¥116,278,277.21 from ¥90,311,445.70 at the beginning of the year, representing a growth of approximately 29%[116]. - The company's total assets at the end of the reporting period were ¥2,203,980,410.94, a 4.39% increase from ¥2,111,282,192.35 at the end of the previous year[18]. - The total liabilities increased to CNY 381,390,761.21 as of June 30, 2022, compared to CNY 368,989,659.95 at the start of the year, marking an increase of about 3.6%[118]. Investment and R&D - Research and development expenses increased by 29.52% to CNY 23,042,775.48, compared to CNY 17,791,098.85 in the same period last year[32]. - The company has committed to continuous investment in drug research and development, with a focus on the consistency evaluation of generic drugs, despite the high costs and risks involved[60]. - The company plans to enhance its research and development capabilities to innovate new technologies and products[137]. - The company aims to improve operational efficiency through potential mergers and acquisitions in the upcoming fiscal year[142]. Product and Market Strategy - The company's main product, Si Mo Tang oral liquid, is a unique product in the market and has been included in the national medical insurance directory[28]. - The marketing strategy has been optimized to adapt to industry changes, focusing on specialized operations across different market segments[27]. - The company plans to diversify its product offerings to support sustainable profit growth in the future[28]. - The company plans to expand its market presence and invest in new product development to drive future growth[141]. Risk Management and Compliance - The company emphasizes the importance of risk awareness regarding future plans and development strategies[3]. - The company faces risks related to raw material procurement, particularly for traditional Chinese medicine ingredients, which may be affected by environmental factors and resource scarcity[60]. - The company will strengthen quality control measures and adhere to environmental regulations to mitigate production-related risks[61]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[70]. Corporate Governance and Structure - The company has not engaged in any related party transactions during the reporting period[82]. - The company has not reported any significant financial indicators affected by share changes[101]. - The company has five subsidiaries included in the consolidation scope as of June 30, 2022, indicating a stable operational structure[150]. - The financial report was approved by the fifth board of directors on August 26, 2022, ensuring compliance with regulatory standards[150]. Future Outlook - Future guidance indicates a cautious outlook with expected revenue growth of 2.3% for the next half-year[141]. - The company aims to optimize its product structure and actively seek acquisition opportunities to diversify its product offerings and create new profit growth points[61].

Financial Performance - The company's revenue for Q1 2022 was CNY 248,851,389.62, representing a 5.72% increase compared to CNY 235,387,600.31 in the same period last year[3] - Net profit attributable to shareholders was CNY 51,824,070.34, up 13.32% from CNY 45,731,537.24 year-on-year[3] - The total operating revenue for Q1 2022 was CNY 248,851,389.62, an increase of 5.8% compared to CNY 235,387,600.31 in Q1 2021[18] - The net profit for Q1 2022 reached CNY 51,824,070.34, representing a growth of 13.5% from CNY 45,731,537.24 in the same period last year[19] - The total comprehensive income for Q1 2022 was CNY 49,185,657.62, compared to CNY 41,997,646.77 in the same period last year, marking an increase of 17.5%[20] - The company's diluted earnings per share increased by 13.31% to CNY 0.1030 from CNY 0.0909 in the previous year[3] - The basic earnings per share for Q1 2022 was CNY 0.1030, an increase from CNY 0.0909 in Q1 2021[20] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 37.91% to CNY 44,016,378.08, down from CNY 70,886,845.47 in the previous year[3] - The cash inflow from operating activities was CNY 249,825,439.23, compared to CNY 242,374,291.24 in the previous year, indicating a growth of 3.0%[21] - The total cash and cash equivalents at the end of Q1 2022 amounted to ¥90,759,367.83, down from ¥133,986,934.55 at the end of Q1 2021[23] - The company reported a total cash outflow from operating activities of ¥205,809,061.15, which is an increase from ¥171,487,445.77 in Q1 2021[23] - The company reported a decrease in cash and cash equivalents by 98.53%, totaling CNY 1,000,000.00 compared to the previous year[8] Research and Development - R&D expenses increased by 35.74% to CNY 8,598,000.00, primarily due to enhanced investment in the consistency evaluation of isoniazid tablets and iodinated contrast agents[6] - Research and development expenses increased to CNY 8,682,027.43, up 35.7% from CNY 6,396,211.92 in Q1 2021[18] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,132,384,519.04, a 1.00% increase from CNY 2,111,282,192.35 at the end of the previous year[3] - The total current assets are RMB 560,644,902.53, up from RMB 535,410,439.63 at the beginning of the year, reflecting a growth of approximately 4.3%[15] - The accounts receivable increased to RMB 245,321,781.67 from RMB 207,401,998.50, indicating a growth of about 18.3%[15] - The total liabilities decreased to CNY 340,906,329.02 from CNY 368,989,659.95 year-over-year, reflecting a reduction of approximately 7.6%[17] - The company's short-term borrowings decreased to RMB 102,901,468.00 from RMB 131,791,855.05, a reduction of approximately 22%[15] Shareholder Information - The total number of common shareholders at the end of the reporting period is 46,670[10] - The largest shareholder, Hainan Hansen Holdings (Limited Partnership), holds 42.13% of the shares, totaling 212,006,189 shares[10] - The total number of shares held by the top ten unrestricted shareholders includes 212,006,189 shares held by Hainan Hansen Holdings[10] Other Financial Activities - The company completed the registration of business changes and received a new business license on January 8, 2022[12] - The company plans to invest up to RMB 10 million as a limited partner in an industry investment fund with Shenzhen Rongyu Capital Management Co., Ltd.[12] - The company recorded a total of CNY 551,165.57 in non-recurring gains and losses for the reporting period[5] Operating Costs - The total operating costs for Q1 2022 were CNY 199,935,352.92, slightly up from CNY 197,880,670.79 in Q1 2021[18] - The company reported a decrease in sales expenses to CNY 105,570,433.08 from CNY 108,676,129.07 year-over-year, a reduction of 2.0%[18] Audit and Reporting - The company did not conduct an audit for the Q1 2022 report[24] - The report was released by the board of directors on April 28, 2022[25]